MODERN METHODS OF TREATMENT OF PATIENTS WITH ANKYLOSING SPONDYLITIS
DOI:
https://doi.org/10.37547/ijasr-02-11-17Keywords:
Ankylosing spondylitis, treatments, basic antirheumatic drugs, IL-17 inhibitorsAbstract
The review article presents modern methods of treatment of ankylosing spondylitis, including the use of both non-drug and drug therapy. Of the medical methods of treatment, a critical review of the available modern drugs, including their shortcomings, is presented. The article also points out the lack of clear recommendations for the introduction and treatment of AS patients during the pandemic, taking into account the incidence of COVID-19.
Downloads
References
Aбдурахманова Н.М. Клинико-иммунологические особенности и новые подходы лечебно- профилактических мер при анкилозирующим спондилоартрите у больных, перенесших COVID–19. Диссер доктора наук. 2022. с.200.
Черенцова И.А., Оттева Э.Н. Особенности течения анкилозирующего спондилита на разных стадиях у мужчин и женщин // Современная ревматология –№2, –2019, – С. 73-79.
Эрдес Ш.Ф. Последние достижения и перспективы терапии аксиального спондилоартрита / анкилозирующего спондилита // Современная ревматология. –2021, –№15(2). –С.94-105.
Abdurakhmanova N.M. et al. Clinical and diagnostic significance of Anti- CD74 in Uzbek ankylosing spondylitis patients. Journal of Positive School Psychology. Vol 6. #6, 2022 p 9358-9364
Akhmedov K.S. et al. Influence of accepting basic antirheumatic therapy for ankylosing spondyloarthritis on the clinical course COVID -19 //Academicia: An International Multidisciplinary Research Journal. Vol. 12, Issue 07, July 2022 р. 71-76.
Akkoc N, Khan MA. ASAS classification criteria for axial spondyloarthritis: time to modify// Clin Rheumatol. 2016;35(6):1415-1423. doi:10.1007/s10067-016-3261-6
Blair H. A. Secukinumab: A Review in Ankylosing Spondylitis // Drugs. –2019. Т. 79. № 4. C. 433–443.
Chen, Rongjuan et al. Immunological Changes in Peripheral Blood of Ankylosing Spondylitis Patients during Anti-TNF-α Therapy and Their Correlations with Treatment Outcomes // Journal of immunology research vol. 2021 1017938. 15 Oct. –2021, doi:10.1155/2021/1017938
Crossfield SSR, Marzo-Ortega H, Kingsbury SR et al. Changes in ankylosing spondylitis incidence, prevalence and time to diagnosis over two decades // RMD Open. –2021 Dec;7(3):e001888. doi: 10.1136/rmdopen-2021-001888. PMID: 34887345;
Da Cruz Fernandes IM, Pinto RZ, Ferreira P, Lira FS. Low back pain, obesity, and inflammatory markers: exercise as potential treatment // J Exerc Rehabil. –2018 Apr 26;14(2):168-174. doi: 10.12965/jer.1836070.035
Deodhar A, van der Heijde D, Gensler LS et al. COAST-X Study Group. Ixekizumab for patients with non-radiographic axial spondyloarthritis (COAST-X): a randomised, placebo-controlled trial // Lancet. –2020 Jan 4;395(10217):53-64. doi: 10.1016/S0140-6736(19)32971-X. Epub 2019 Dec 5.
Deodhar A, van der Heijde D, Sieper J, et al. Safety and Efficacy of Upadacitinib in Patients With Active Ankylosing Spondylitis and an Inadequate Response to Nonsteroidal Antiinflammatory Drug Therapy: One-Year Results of a Double-Blind, Placebo-Controlled Study and Open-Label Extension. Arthritis Rheumatol. –2022 Jan;74(1):70-80. doi: 10.1002/art.41911. Epub 2021 Nov 12. PMID: 34196498; PMCID: PMC9299108.
Dubash S. The advent of IL-17A blockade in ankylosing spondylitis: secukinumab, ixekizumab and beyond // Expert Review of Clinical Immunology. –2019. Т. 15. № 2. C. 123–134.
Gaydukova I. Z. et al. Stable high interleukin-17A concentration in patients with ankylosing spondylitis treated with tumor necrosis factor-α inhibitors during a year // Terapevticheskii Arkhiv. –2017. № 4 (89). C. 80–85.
Heijde D. van der et al. 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis // Annals of the Rheumatic Diseases. –2017. № 6 (76). C. 978–991.
Hu X, Chen J, Tang W, Chen W, Sang Y, Jia L. Effects of exercise programmes on pain, disease activity and function in ankylosing spondylitis: A meta-analysis of randomized controlled trials. // Eur J Clin Invest. –2020 Dec;50(12):e13352. doi: 10.1111/eci.13352. Epub 2020 Aug 11.
Jeffrey R. Curtis et al. The Annual Diagnostic Prevalence of Ankylosing Spondylitis and Axial Spondyloarthritis in the United States Using Medicare and MarketScan Databases. ACR Open Rheumatol. –2021 Nov; 3(11): 743–752.
Jiang Y, Yang M, Zhang Y, Huang Y, Wu J, Xie Y, Wei Q, Liao Z, Gu J. Dynamics of Adaptive Immune Cell and NK Cell Subsets in Patients With Ankylosing Spondylitis After IL-17A Inhibition by Secukinumab // Front Pharmacol. –2021 Oct 14;12:738316. doi: 10.3389/fphar.2021.738316.
Katsevman G. A. et al. Efficacy and safety of anti-interleukin-17a monoclonal antibody secukinumab in treatment of ankylosing spondylitis: A meta-analysis // Monoclonal Antibodies in Immunodiagnosis and Immunotherapy. –2020. Т. 39. № 5. C. 160–166.
Kenneth Gordon, Foley P, Krueger JG, et al. Bimekizumab efficacy and safety in moderate to severe plaque psoriasis (BE READY): a multicentre, double-blind, placebo-controlled, randomised withdrawal phase 3 trial [published correction appears in Lancet. –2021 Mar 27; ¬–№10273, р.475-486
Khanna Sharma S, Kadiyala V, Naidu G, Dhir V. A randomized controlled trial to study the efficacy of sulfasalazine for axial disease in ankylosing spondylitis. //Int J Rheum Dis. –2018 Jan;21(1):308-314.
Mohanakrishnan R, Beier S, Deodhar A. Tofacitinib for the treatment of active ankylosing spondylitis in adults. // Expert Rev Clin Immunol. –2022 Mar;18(3):273-280. doi: 10.1080/1744666X.2022.2038134. Epub 2022 Feb 21.
Navarro-Compán V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. // Rheum Dis. –2021 Dec;80(12):1511-1521.
Rocha FAC, Pinto ACMD, Lopes JR, Deodhar A. Tumor necrosis factor inhibitors prevent structural damage in hips in ankylosing spondylitis-time to reconsider treatment guidelines? A case series and review of literature. // Clin Rheumatol. –2021 May;40(5):1881-1887.
Van der Heijde D, Song IH, Pangan AL, et al. Efficacy and safety of upadacitinib in patients with active ankylosing spondylitis (SELECT-AXIS 1): a multicentre, randomised, double-blind, placebo-controlled, phase 2/3 trial. Lancet. 2019;394(10214):2108-2117.
Ward MM, Deodhar A, Gensler LS et al. 2019 Update of the American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis // Arthritis Care Res (Hoboken). –2019 Oct;71(10):1285-1299. doi: 10.1002/acr.24025. Epub 2019 Aug 21. PMID: 31436026; PMCID:
Wright GC, Kaine J, Deodhar A. Understanding differences between men and women with axial spondyloarthritis. // Semin Arthritis Rheum. 2020 Aug;50(4):687-694. doi: 10.1016/j.semarthrit.2020.05.005. Epub 2020 May 25. PMID: 32521322.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 N.M. Abdurakhmanova, Kh.S. Ahmedov, I.A. Turaev, S.S. Raximov, S.I. Zaripov
This work is licensed under a Creative Commons Attribution 4.0 International License.
